文献速递慢性静脉疾病

ATLANTIS随机对照试验:水中运动治疗慢性静脉功能不全

The randomized, controlled ATLANTIS trial of aquatic therapy for chronic venous insufficiency.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-10-28

ATLANTIS随机对照试验将201例晚期慢性静脉功能不全(CVI)患者随机分为水中运动组(AG)与对照组(CG),评估水中运动(AA)的临床疗效。主要终点为3个月时改良静脉临床严重程度评分(VCSS)降低≥4分,AG组达标率28%,CG组3%(OR=12.08,95%CI:3.51-41.59,P<.001)。结论认为水中运动安全有效,可快速改善临床状态与生活质量并持续至24个月。

要点

  • 水中运动3个月可使28%的晚期CVI患者改良VCSS降低≥4分,对照组仅3%。
  • 水中运动组24个月时VCSS、Villalta评分及腿围改善均显著优于对照组。
  • 水中运动方案为每周3次、每次至少15分钟、速度1 m/s的泳池行走,持续3个月。

核心结论

  • 在晚期CVI治疗中加入水中运动安全有效,可显著改善临床状态和生活质量。
  • 获益在开始水中运动后3个月内快速出现,并在3个月至2年间以较慢速度持续改善。

研究设计与样本

  • 随机前瞻性开放标签试验,共纳入201例晚期CVI患者,随机分为水中运动组(AG)和对照组(CG)。
  • 水中运动组91例、对照组90例完成24个月随访。
  • 主要疗效终点为3个月时改良VCSS降低≥4分。

主要发现

  • 3个月时改良VCSS降低≥4分者AG组28%、CG组3%(OR=12.08;95%CI:3.51-41.59;P<.001)。
  • 基线至24个月变化:改良VCSS -4.08±2.08 vs -1.15±1.26,Villalta评分 -4.00±2.68 vs -1.01±1.34(P<.001)。
  • 大腿周径 -3.40±1.78 cm vs -1.40±2.55 cm,小腿周径 -1.27±1.34 cm vs -0.49±1.21 cm(P<.001)。
  • SF-36躯体健康成分 3.82±2.36 vs 1.16±1.18,VEINES-QoL 3.35±1.67 vs 1.30±1.43,VEINES-Sym 3.53±1.71 vs 1.23±1.26(P<.001)。

关键数值与推荐

  • 水中运动方案:泳池内以1 m/s速度行走,每次至少15分钟,每周3次,持续3个月。
  • 主要终点阈值:3个月时改良VCSS降低≥4分。

临床怎么用

  • 可将水中运动作为晚期CVI的辅助治疗,推荐每周3次、每次至少15分钟、速度1 m/s的泳池行走,持续3个月。
  • 水中运动起效快,3个月内即可观察到VCSS和生活质量改善,长期坚持可维持并缓慢进一步改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are conflicting reports on the efficacy of exercise in chronic venous insufficiency (CVI). Exercise in water or aquatic activity (AA) can have additional advantages. We sought to evaluate the clinical effects of AA in CVI in a randomized prospective open label fashion. METHODS: A total of 201 patients with advanced CVI were randomized to receive AA vs no such treatment. In the Aquatic Group (AG), 91 patients reached the 24-month follow-up point, and in the Control Group (CG), 90 patients did. The primary efficacy end point was a predefined reduction of ≥4 points in the modified Venous Clinical Severity Score (VCSS) at 3 months. Instruments of venous disease severity and quality of life were compared at baseline, 3 months, and 24 months between and within the two groups. These included the modified VCSS, Villalta score, leg and thigh circumference, the Physical Health Component of the 36-Item Short Form Health Survey, and the Venous Insufficiency Epidemiological and Economic Study Quality of Life/Symptom scores. Aquatic activity consisted of a minimum of 15 minutes of walking in a swimming pool at 1 m/s, 3 times/wk for 3 months. RESULTS: The primary end point of 4-point reduction in the modified VCSS at 3 months was reached in 28% of AG and 3% of CG (odds ratio = 12.08; 95% confidence interval: 3.51, 41.59; P < .001). Comparison of changes in secondary end points from baseline to 24 months between AG and CG demonstrated the following: modified VCSS -4.08 ± 2.08 vs -1.15 ± 1.26, Villalta score -4.00 ± 2.68 vs -1.01 ± 1.34, thigh circumference -3.40 ± 1.78 cm vs -1.40 ± 2.55 cm, leg circumference -1.27 ± 1.34 cm vs -0.49 ± 1.21 cm, Physical Health Component of the 36-Item Short Form Health Survey 3.82 ± 2.36 vs 1.16 ± 1.18, Venous Insufficiency Epidemiological and Economic Study Quality of Life 3.35 ± 1.67 vs 1.30 ± 1.43, and Venous Insufficiency Epidemiological and Economic Study Symptom 3.53 ± 1.71 vs 1.23 ± 1.26 (P < .001 for all comparisons; ± denotes mean ± standard deviation). CONCLUSIONS: The addition of AA to the treatment of patients with advanced CVI is safe and effective, leading to a significant improvement in clinical status and quality of life. These beneficial changes occur rapidly within 3 months of initiation of AA and are continued at a slower rate of improvement from 3 months to 2 years.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Sharifi M, Bay RC, Karandish K, et al. The randomized, controlled ATLANTIS trial of aquatic therapy for chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33127467. doi:10.1016/j.jvsv.2020.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。